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 Obesity is associated with a low-grade chronic inflammation with increased 
levels of proinflammatory markers in the circulation and local inflammation 
in the adipose tissue. In this thesis, two aspects of obesity-related 
inflammation have been studied. Macrophages in the adipose tissue and the 
moderately elevated serum levels of serum amyloid A (SAA) derived from 
the adipose tissue have both been suggested as possible players behind 
obesity-related comorbidities in humans. The aim of this thesis was to 
investigate if there are obesity-independent links between adipose tissue 
macrophages and metabolic dysfunction and to examine if adipose tissue-
derived SAA contributes to the development of insulin resistance, obesity-
related inflammation and atherosclerosis.  
Adipose tissue gene expression of macrophage markers was analyzed in 
relation to anthropometric and metabolic parameters in the Swedish Obese 
Subjects (SOS) Sib Pair study. The gene expression of macrophage markers 
was associated with insulin sensitivity and serum lipid levels and these 
associations remained, although weakened, when the analysis was adjusted 
for BMI. The link between adipose tissue macrophages and insulin sensitivity 
was confirmed by showing that the adipose tissue gene expression of 
macrophage markers was increased in patients with type 2 diabetes mellitus 
compared to their BMI-matched non-diabetic controls.  
To investigate the effects of adipose tissue-derived SAA, a hSAA+/- 
transgenic mouse model (hSAA1 mice) where human SAA1 is specifically 
expressed in the adipose tissue was established. When the hSAA1 mice were 
fed normal chow or high fat diet, the serum levels of SAA resembled those in 
lean and obese humans, respectively. The circulating SAA was found in the 
high density lipoprotein (HDL)-containing FPLC fractions indicating an 
association of SAA to high density lipoprotein. This is an important finding 
since lipid-free SAA has other functions than SAA associated with HDL. The 
hSAA1 mice fed a high fat diet displayed similar glucose and insulin 
responses during an oral glucose tolerance test compared to their wild type 
littermates. In addition, the adipose tissue mRNA levels of genes related to 
insulin sensitivity were not decreased. Circulating levels of proinflammatory 
markers and gene expression of macrophage markers in the adipose tissue 
were not increased in hSAA1 mice. Hence, the hSAA derived from adipose 
tissue did not affect local and systemic insulin sensitivity or obesity-related 
inflammation in our mouse model. To investigate possible effects of adipose 
tissue-derived hSAA1 on the development of atherosclerosis, the hSAA1 
mice were crossbred with ApoE-/- mice. Analyses of en face prepared aortas 
from hSAA+/-/ApoE-/- mice displayed similar atherosclerotic lesion areas in 
all sections of the aorta compared to wild type mice.  
In conclusion, adipose tissue gene expression of macrophage markers is 
increased in type 2 diabetes mellitus and linked to insulin sensitivity and 
serum lipid levels independent of obesity. Furthermore, despite extensive 
research and several different experimental setups, we find no evidence for a 
causal role of adipose tissue-derived hSAA in the development of insulin 
resistance, obesity-related inflammation or atherosclerosis in hSAA1 mice.   
Keywords: Adipose tissue, macrophages, serum amyloid A, obesity, insulin 
sensitivity, atherosclerosis. 
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 Fetma är associerat med en kronisk låggradig inflammation i fettväven med 
ökad infiltration av makrofager och med måttligt förhöjda nivåer av 
akutfasproteinet serum amyloid A (SAA) i blodet. De förhöjda nivåerna av 
SAA har visat sig härstamma från fettväven hos feta individer. Både 
makrofager i fettväven och de förhöjda nivåerna av SAA skulle kunna vara 
delar av orsaken till varför fetma ofta leder till metabola störningar såsom 
insulin resistens och kärlförkalkning men det finns också en möjlighet att de 
bara är inerta markörer för metabol dysfunktion. Syftet med studierna i denna 
avhandling var att klargöra om fettvävsmakrofager är associerade till 
metabola störningar oberoende av fetmagrad och att studera om 
fettvävsproducerat SAA kan bidra till utvecklingen av metabol sjukdom.  
Genuttrycket av markörer för makrofager mättes i fettväv och analyserades 
mot metabola parametrar i Swedish Obese Subject (SOS) Sib Pair study. 
Analysen visade att uttrycket av makrofagmarkörer i fettväv var kopplat till 
insulinkänslighet samt till kolesterol- och fettnivåer i blodet även när 
analysen justerades för inverkan av fetma. Sambandet mellan 
fettvävsmakrofager och insulinkänslighet undersöktes vidare genom att 
analys av genuttrycket av makrofagmarkörer i fettväven hos patienter med 
typ 2 diabetes jämfördes mot uttrycket hos friska BMI-matchade kontroller. 
Här kunde sambandet mellan insulinkänslighet och fettvävsmakrofager 
stärkas ytterligare då genuttrycket av makrofagmarkörer i fettväv var högre 
hos patienterna med typ 2 diabetes.  
För att studera hur fettvävsproducerat SAA påverkar metabol sjukdom 
utvecklades en transgen musmodell med specifikt uttryck av humant SAA i 
fettväven. Musmodellen uppvisar liknande cirkulerande nivåer av humant 
SAA som de som finns hos smala och feta människor. Det humana proteinet 
återfinns associerat till high density lipoprotein (HDL) vilket är ytterligare en 
viktig faktor för att musmodellen ska efterlikna människa. Möss som 
utfodrats med högfettsdiet genomgick ett oralt glukostoleranstest för att få en 
uppfattning om hur mössen reagerade på en hög dos glukos. Glukos- och 
insulinnivåerna som uppmättes påvisade inte någon insulinresistens hos de 
transgena mössen jämfört med en grupp kontrollmöss. Den lokala 
insulinkänsligheten i fettväven undersöktes genom att analysera genuttrycket 
av gener viktiga för insulinsignalering. De transgena mössen uppvisade inga 
sänkta genexpressionsnivåer av dessa gener vilket tyder på att 
insulinresistensen i fettväven inte förvärrades av den lokala produktionen av 
SAA. De hSAA1 transgena mössen undersöktes även med avseende på 
infiltration av makrofager i fettväven och nivåer av inflammatoriska markörer 
i blodet som vanligtvis är förhöjda vid fetma. Genuttrycket av 
makrofagmarkörer var oförändrat i fettväv hos transgena möss och de 
uppvisade inte heller några förhöjda nivåer av inflammatoriska markörer i 
blodet jämfört med en grupp kontrollmöss. För att undersöka huruvida 
fettvävsproducerat SAA påverkar kärlförkalkning avlades de transgena 
mössen mot en musstam som saknar apolipoprotein E och som spontant 
utvecklar kärlförkalkning. De transgena mössen uppvisade dock ingen 
skillnad i omfattning av kärlförkalkning jämfört med kontrollmöss.   
Sammanfattningsvis har denna avhandling visat att fettvävsmakrofager är 
länkade till metabol dysfunktion oberoende av fetma och att diabetiker 
uppvisar förhöjda nivåer av fettvävsmakrofager i jämförelse med en frisk 
BMI-matchad kontrollgrupp. Avhandlingen rapporterar även om 
utvecklingen av en ny transgen musmodell som har ett specifikt uttryck av 
humant SAA i fettväven och som uppvisar nivåer av SAA som hos smala och 
feta individer. Studier i denna musmodell har dock inte kunnat påvisa att 
fettvävsproducerat SAA kan orsaka nedsatt insulinkänslighet eller ge upphov 
till fetmaassocierad inflammation. Ett kausalt samband mellan 
fettvävsproducerat SAA och kärlförkalkning har ej heller kunnat påvisas. 
Detta indikerar att de förhöjda nivåerna av SAA som finns vid fetma inte är 
en orsak till metabol sjukdom utan fungerar som en markör för metabol 
sjukdom.       
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Obesity is a condition with excess accumulation of body fat [1]. Normal 
percentages of body fat range between 15-20 percent in men and 25-30 
percent in women [1]. In obesity, individuals can have more than 50 % body 
fat. There are many methods that can be used to estimate body fat such as 
magnetic resonance imaging, computed tomography, and dual energy x-ray 
absorptiometry (DEXA). However, these methods are time consuming and 
expensive. Alternatively, anthropometric measures such as sagittal diameter, 
waist-to-hip ratio (WHR) and body mass index (BMI) can be used to estimate 
body composition [2].  
Today, BMI is one of the most common methods used to estimate obesity. 
BMI is calculated by dividing weight (kg) with height squared (m2). Despite 
individual variations, there is a good correlation between BMI and body fat in 
large populations [1]. The World Health Organization uses weight 
classification based on BMI where BMI < 18.5 = underweight, BMI 18.5-25 
= normal weight, BMI 25-30 = overweight, BMI > 30 obese and BMI > 40 = 
morbidly obese [3]. Many epidemiological studies of obesity are also based 
on this classification.  
 
Over the last 30 years there has been a dramatic increase in obesity world-
wide [4-6]. Reports have estimated that 1.46 billion adults are overweight and 
of these, 205 million men and 297 million women are obese [6]. As much as 
33 % of the US population is considered as obese [7] whereas prevalence 
data for Sweden show that 15 % of men and 14 % of women are obese and an 
additional 28 percent of women and 42 % of men are overweight [8].  
 
Obesity is caused by an imbalance between energy intake and energy 
expenditure where the surplus energy is stored mainly as fat [9].The changes 
in human life style during the last decades, with a more sedentary life style 
and easily accessible food have contributed to the development of an obesity 
epidemic. However, studies in twins have shown that much of the individual 
variation in adiposity is due to genetic factors [10-12]. There are 
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monogenetic causes of obesity such as defects in the leptin signaling system 
but these are rare and the majority of obesity development is probably a 
combination of environmental changes and genetic susceptibility.      
Many hypotheses have been presented to explain why humans are prone to 
develop obesity. According to the “thrifty genotype hypothesis” presented in 
1962, genetic variants that promote efficient energy uptake and storage of 
surplus energy as fat had survival benefits in times of starvation [13]. An 
alternative hypothesis suggests that obesity-related genotypes have never 
been under evolutionary pressure until now since humans never lived under 
conditions of food excess. Thus, genetic variants causing obesity should be 
considered to be a result of genetic drift [14].  
 
Obesity is part of the metabolic syndrome which is a clustering of metabolic 
disturbances often occurring together. There are different classifications of 
the metabolic syndrome but all include central obesity, prediabetes, 
hypertension and dyslipidemia and are all risk factors for cardiovascular 
disease [15-23]. Several other severe conditions such as fatty liver disease, 
cancer, atherosclerosis and sleep apnea are also linked to obesity [24-26] and 
obesity is associated with reduced life expectancy [27].  
Insulin resistance is a part of the development of type 2 diabetes mellitus [28] 
and in parallel with increasing obesity prevalence, the prevalence of diabetes 
has increased as well [29]. The global prevalence of type 2 diabetes mellitus 
was estimated to 171 million people in 2000 and 366 million people are 
predicted to be affected in 2030 [30]. Both obesity and type 2 diabetes 
mellitus are risk factors for atherosclerosis, the major underlying cause of 
cardiovascular disease, a common cause of death worldwide [31,32]. 
However, the molecular mechanisms behind obesity-related disorders are, 
despite intensive research, still only partly understood.  
 
Obesity is a condition that is difficult to treat. Treatment of obesity involves 
lifestyle modifications with restricted caloric intake and increased physical 
activity.  However, it is hard to achieve long-term weight reduction using 
caloric restriction and a majority of people later regain the lost weight 
[33,34]. Today, bariatric surgery is the most effective way to obtain a long-
term weight reduction [34]. Bariatric surgery also improves metabolic risk 
factors, prevents type 2 diabetes mellitus, lowers the risk for cancer, prevents 
fatal and non-fatal cardiovascular events and prevents premature death [34-
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38]. However, it is neither possible nor desirable to operate all obese patients 
and molecular mechanisms behind obesity and obesity-related disorders need 
to be further investigated in order to find alternative treatment strategies.   
 
Systemic insulin resistance is a result of impaired insulin action in 
metabolically active tissues and a part of the development of type 2 diabetes 
mellitus [28].  
Insulin is an anabolic hormone that induces glucose uptake in metabolically 
active tissues such as skeletal muscle, adipose tissue and the liver. Insulin is 
produced in and released from the β-cells in the pancreas and mediates 
glucose uptake via the binding to the insulin receptor (IR) on the cell surface. 
The binding of insulin to its receptor initiates a signaling cascade with 
subsequent tyrosine phosphorylation of insulin receptor substrate-1 and 
insulin receptor substrate-2 (IRS-1 and IRS-2). The cascade results in a 
translocation of glucose transporter type 4 (GLUT4) to the cell membrane 
and promotes glucose uptake [28,39]. The glucose is either used for ATP 
production or processed and stored as glycogen or fat within the cell. Insulin 
also regulates other processes such as protein translation and cellular 
hypertrophy and has the ability to suppress lipolysis in the adipose tissue 
[40].      
In insulin resistance, there is a decreased glucose transport into the cells and 
insulin has an impaired ability to inhibit lipolysis in the adipose tissue [41].  
The insulin resistance in the liver also leads to reduced suppression of 
gluconeogenesis and stimulation of free fatty acid production. This results in 
the hyperglycemia and hypertriglyceridemia that are characteristic of type 2 
diabetes mellitus.   
 
Dyslipidemia associated with obesity and the metabolic syndrome is 
characterized by hypertriglyceridemia and low levels of high density 
lipoprotein (HDL) cholesterol [17,20]. These changes are also accompanied 
by an increase in small dense LDL-particles. The hypertriglyceridemia in 
obesity-related dyslipidemia is partly due to insulin resistance as described in 
1.2.  
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HDL is considered to have atheroprotective properties [42] and a low level of 
HDL cholesterol is a risk factor for cardiovascular disease [43]. HDL and its 
structural protein apolipoprotein AI play a major role in the reverse 
cholesterol transport [42] where cholesterol from peripheral tissues are 
transferred to HDL and ApoAI via the ATP-binding cassette transporters  
ABCA1 and ABCG1 for transport to the liver [44]. Cholesterol can not be 
degraded in peripheral tissues and has to be transported to the liver for biliary 
secretion. Hence, reverse cholesterol transport is considered important for 
protecting the peripheral tissues from lipid overload.  
 
Atherosclerosis is a progressive disease where atherosclerotic lesions are 
formed in the vessel wall [45]. The early stages of atherosclerotic lesions 
consist of small lipid deposits in the arterial intima that progress into “fatty 
streaks”. The fatty streaks consist of lipoproteins and cholesterol-esters and 
are characterized by the presence of lipid loaded macrophages, “foam cells”, 
in the intimal layer of the vessel. These initial lesions are present early in life 
and can develop into more advanced lesions. [45]. In the more advanced 
atherosclerotic lesions there are more extracellular lipid deposits with 
calcium that deform the intimal layer of the vessel and this can also affect the 
media and adventitia. In addition, foam cells, macrophages and lymphocytes 
without intracellular lipid accumulation are found within the lesion. 
Furthermore, in advanced stages of atherosclerotic lesions an overlying 
fibrous tissue cap is formed. Advanced atherosclerotic lesions can lead to 
clinical consequences, especially when there is a disruption of atherosclerotic 
lesion surface that causes thrombosis or emboli with a subsequent occlusion 
of the vessel [46].    
The subendothelial proteoglycans are considered to play a role in the 
retention of the lipoproteins in the vessel wall [47,48]. Within the vessel wall, 
the lipoproteins are modified by oxidation which further contributes to the 
lesion formation [49]. The accumulation of lipoproteins in the vessel wall is 
more pronounced in regions exposed to mechanical forces [45] indicating 
that mechanical stress is an important factor for atherosclerosis development. 
Macrophages and lymphocytes are present in the atherosclerotic lesion [46] 
but the triggering signals for infiltration in the vessel wall and what triggers 
the transformation of macrophages into foam cells are not clear. Hence, the 
development of atherosclerotic lesions is complex and more studies are 
needed to identify mechanisms leading to atherosclerosis development.    
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One of the main functions of the adipose tissue is to serve as a long-term 
reserve of energy [50]. In times of positive energy balance, surplus energy 
can be stored as triglycerides in the adipose tissue [50]. During starvation, the 
adipose tissue is able to hydrolyze the triglycerides into free fatty acids and 
glycerol providing an energy source for other tissues [50,51]. Lipolysis is 
catalyzed by adipose triglyceride lipase and hormone sensitive lipase. The 
lipolysis is normally inhibited by insulin and stimulated by catecholamines 
[52] but is also known to be regulated by other hormones such as 
glucocorticoids [53].  
The adipose tissue has many other functions in the body. It is considered to 
function as a thermal insulation and a protection against mechanical injuries 
[50]. The adipose tissue is also involved in the metabolism of steroid 
hormones such as glucocorticoids and sex hormones [54].   
 
The adipose tissue does not only contain adipocytes but also a variety of 
other cell types such a endothelial cells, fibroblasts, preadipocytes and 
pericytes as well as inflammatory cells including macrophages, mast cells 
and lymphocytes [55]. The white adipose tissue is distributed in different 
depots that can be divided into intra-abdominal (“visceral”) and subcutaneous 
adipose tissue. Men and women have a tendency to store fat in different 
adipose tissue depots. Men store their fat to a larger extent intraabdominally 
than women, who have a tendency to store their fat in the subcutaneous 
depots.  
In obesity, adipose tissue expands and is remodeled due to increasing 
demands in fat storing capacity. The fat storing capacity can be increased as a 
result from hyperplasia with increased number of adipocytes or from 
hypertrophy of adipocytes [55-57]. There is a stronger association between 
hypertrophic adipocytes and metabolic disease such as insulin resistance than 
hyperplastic adipose tissue with an increased number of smaller adipocytes 
[58]. It has been speculated that a hypertrophic adipocyte may be a signal 
showing that lipid storage capacity has reached its limit. A storage limit in 
adipose tissue could lead to lipid accumulation in other tissues with 
subsequent lipotoxicity and metabolic dysfunction [59,60]. This hypothesis is 
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further supported by the fact that also very little adipose tissue, 
lipodystrophy, causes hyperglycemia and hyperinsulinemia probably due to 
limited fat storing capacity [61-65]. These observations pinpoint the 
importance of the adipose tissue as a factor in glucose homeostasis and 
metabolic disease.  
 
The adipose tissue is not only capable of releasing free fatty acids to provide 
energy for other organs but is also able to produce and release proteins 
involved in body metabolism, blood hemostasis and inflammatory responses 
[54,66-72]. The endocrine function of the adipose was put into focus by the 
discovery of leptin in 1994 when the mutant gene causing obesity in the 
ob/ob mice was found [66]. The adipose tissue is the main source of 
circulating leptin in both mouse and human and is increased in obesity 
[67,68]. Leptin has a major impact on the central control of energy balance in 
the hypothalamus where it suppresses food intake and stimulates energy 
expenditure [73-75]. The role of leptin in human energy balance is well 
illustrated by the few cases of patients who develop early on-set, morbid 
obesity due to leptin deficiency or non-signaling leptin receptors [76].  
Several other proteins secreted from the adipose tissue have been detected 
since the discovery of leptin [70,72,77,78]. The expression and secretion of 
these proteins are often influenced by adiposity and hypertrophic adipocytes 
are known to have an altered production of many adipokines [72,77,79-81]. 
The altered expression of these proteins is suggested to play a role in the 
development of obesity and obesity-related disorders. However, the full 
extent of adipokine impact on metabolic disease is not clear.  
 
Obesity is an inflammatory condition with moderately increased levels of 
inflammatory markers, including IL-6, C-reactive protein and serum amyloid 
A (SAA) [82-89]. In addition, obese individuals display a low-grade chronic 
inflammation locally in the adipose tissue, including increased infiltration of 
macrophages [90,91]. The metabolic dysfunction associated with obesity has 
been suggested to be caused by the obesity-related inflammation [72,90,92]. 
Several studies have investigated different aspects of the obesity-related 
inflammation but more studies are needed to elucidate all mechanisms behind 
this link.   
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Macrophages are present in the adipose tissue of lean and obese individuals 
but numbers are increased in obesity [90,91,93,94]. The macrophages in 
adipose tissue of obese individuals are often found surrounding dying 
adipocytes in so called “crown-like” structures whereas macrophages in lean 
individuals are more interspersed in the adipose tissue [95]. Adipocyte death 
is suggested to be induced by hypoxia and subsequent endoplasmic reticulum 
stress that occur in the expanding adipose tissue in obesity [95-100]. The 
adipocyte death could trigger signals that mediate macrophage infiltration in 
the adipose tissue. Transgenic adipose-tissue specific expression of 
chemoattractants has been shown to have an impact on macrophage 
infiltration in the adipose tissue [101,102] but more studies are needed to 
examine what causes macrophage infiltration into the adipose tissue and what 
role the adipose tissue macrophages play in metabolic dysfunction.  
 
SAA is an apolipoprotein and the SAA gene family members are, similar to 
other apolipoproteins, structured with a four exon and three exon 
organization [103]. Mature SAA proteins contain 104-112 amino acids [104] 
and the SAA gene family is phylogenetically conserved and found in many 
other species [105-108]. The SAA gene family is divided into two groups, 
acute phase SAA (A-SAA) and constitutive SAA (C-SAA) depending on 
activation in response to inflammatory stimuli [104].  
The human SAA gene family comprises at least four members, all clustered 
at chromosome 11p15.1 [109]. SAA1 and SAA2 are the acute phase forms of 
the SAA gene family and display 90% sequence homology [110]. SAA4 is 
the constitutively expressed form of the human SAA gene family and does 
not share the same high sequence homology as SAA1 and SAA2 [111]. 
SAA3 is considered to be pseudogene as it contains a premature stop codon 
and is not transcribed [112].  
In mouse, the SAA gene family is located in the proximal part of 
chromosome 7 [113-115]. Saa1 and Saa2 are considered to be the 
evolutionary homologues to SAA1 and SAA2 and are the acute phase forms 
of mouse SAA [104]. However, in the mouse there is a third acute phase 
form, Saa3 that does not share the same high sequence homology as Saa1 
versus Saa2 and has no specific hepatic expression [116-118]. Saa4 is the 
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constitutive form of mouse SAA and is the evolutionary homologue of the 
human SAA4 [110,115].  
The acute phase forms of SAA are expressed in the liver as a response to 
inflammatory stimuli such as infection or tissue damage [119,120]. The 
hepatic A-SAA expression is induced by the proinflammatory cytokines IL-
1β, TNF-α and IL-6 and the serum levels of SAA can rise 1000-fold during 
acute phase [119-125]. However, extrahepatic expression of A-SAA has also 
been reported in both mouse and human [126-129].  
We and others have shown that the adipose tissue is the main producer of A-
SAA in obese humans in absence of a systemic inflammatory response 
[128,129]. SAA expression is increased in obese individuals and 
hypertrophic adipocytes and obese individuals display moderately elevated 
serum levels of SAA [128,130]. Both SAA gene expression in adipose tissue 
and circulating levels of SAA decrease during weight reduction [128,129]. In 
addition, in vitro studies have shown that SAA release from adipose tissue 
biopsies is correlated with BMI [131]. These data indicate that the elevated 
levels of SAA in obesity are derived from the adipose tissue in humans. The 
chronic moderately elevated levels of SAA found in obesity are linked to 
both insulin resistance and atherosclerosis [84,86,89,132,133]. Several 
mechanisms behind this link have been suggested but the actual role of 
adipose tissue-derived SAA in metabolic disease is still unknown.  
The fact that the SAA gene family is highly phylogenetically conserved and 
that there is a rapid and massive induction as a response to inflammatory 
stimuli during the acute phase indicate that SAA has important functions in 
the body [110]. Many different studies have therefore been performed to 
investigate the possible roles of SAA. 
SAA is an apolipoprotein and associates with HDL in the circulation (HDL-
SAA) [134-136]. It has been suggested that SAA may play a role in the 
reverse cholesterol transport during the acute phase (Figure 1). However, the 
role for SAA in reverse cholesterol transport is disputed. HDL-SAA displays 
reduced affinity for hepatocytes and higher affinity for macrophages [137]. 
This has been interpreted as HDL being redirected to activated macrophages 
in the acute-phase. One hypothesis states that SAA affects reverse cholesterol 
transport in order to provide damaged cells with lipids for regeneration 
[138,139] and it has been found that overexpression of human SAA1 in mice 
impairs HDL-mediated reverse cholesterol transport [140]. Others suggest 
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that SAA removes excess cholesterol from sites of injury [141]. Both 
administration of mouse SAA2 and peptides of mouse SAA2 in a liposomal 
solution promote cholesterol efflux from macrophages both in vivo and in 
vitro [142-144], suggesting that SAA may facilitate reverse cholesterol 
transport. The suggested SAA-induced changes in reverse cholesterol 
transport may also have anti- or proatherogenic effects if it affects the extent 
of lipid accumulation in the vessel wall. Other suggested functions for SAA 
during the acute phase include a role in tissue repair. Recombinant human 
SAA1/2 induces the expression of matrix metalloproteinases that degrade the 
extracellular matrix in vitro [145,146]. Recent studies have reported mRNA 
levels of SAA in human and mouse atherosclerotic lesions [147-149]. A local 
production of SAA in the vessel wall could lead to atherosclerotic lesion 
rupture and subsequent thrombosis if SAA is able to induce matrix 
metalloproteinases in vivo. 
Several other mechanisms where SAA could affect atherogenesis 
development have been suggested and are summarized in Figure 1. SAA may 
promote lipoprotein retention in the vessel wall. SAA has a binding site for 
heparan sulfate [150] and mouse acute-phase SAA facilitates the binding of 
HDL to proteoglycans in vitro [151]. In addition, SAA stimulates 
proteoglycan synthesis in vascular smooth muscle cells in vitro and in vivo 
[152], which potentially could lead to increased lipoprotein retention in the 
vessel wall. Moreover, recombinant human SAA1/2 induces foam cell 
formation in cultured mouse macrophages [153,154], which could promote 
atherosclerosis development.   
The association of SAA to HDL is suggested to affect the protective anti-
inflammatory properties of HDL in atherosclerosis. Recombinant human 
SAA1/2 in association with HDL reduces HDL’s ability to inhibit MCP-1 
expression in vascular smooth muscle cells [155] and the recombinant protein 
stimulates cytokine and chemokine expression in both macrophage and 
endothelial cell lines [156,157]. In addition, recombinant SAA1/2 up 
regulates cell adhesion molecules in cultured endothelial cells [157,158] and 
exhibits chemoattractant effects on monocytes and neutrophils [159-161]. 
This could lead to the recruitment of macrophages in the vessel wall and 
contribute to the vessel wall inflammation.  
The reported proinflammatory properties of SAA may also be of importance 
for obesity-related inflammation with increased levels of inflammatory 
markers in the circulation and increased infiltration of macrophages in the 
adipose tissue. Increased macrophage infiltration into adipose tissue may 
affect insulin resistance [101,102]. Hence, SAA could indirectly affect 
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insulin sensitivity if SAA acts as a chemoattractant in the adipose tissue. 
However, SAA may also directly affect insulin resistance as recombinant 
SAA reduces mRNA levels of genes related to insulin sensitivity in 
adipocytes [162-164]. 
Some of the functions of SAA presented here could be mediated via different 
SAA receptors [165-173]. Reports have suggested importance of SAA 
receptors in processes such as cholesterol efflux, glucose homeostasis, 
chemotaxis and inflammatory signaling. However, most of these receptors 
are not specific for SAA and most of the receptors have been identified as 
receptors for the recombinant SAA1/2 and not the endogenous SAA.  
Taken together, SAA has been suggested to be involved in many different 
processes including cholesterol transport, insulin resistance, inflammation 
and the development of atherosclerotic lesions. However, many studies 
investigating SAA function have been performed using a recombinant and/or 
de-lipidated SAA [145,154-157,159-163]. The recombinant protein is a 
consensus SAA molecule which corresponds to SAA1α except for an N-
terminal methionine and substitution of asparagine for aspartic acid at 
position 60 and arginine for histidine at position 71. We and others have 
shown that the recombinant protein does not share the same functions as the 
endogenous SAA [174,175] and the physiological relevance of the 
recombinant protein is unclear. There are a limited number of in vivo studies 
investigating the role of SAA in metabolic disease and the role of adipose 
tissue-derived SAA is still obscure. Hence, further research is needed to 
elucidate if SAA plays a causal role in the development of metabolic disease.   
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Figure 1. Suggested proatherogenic functions of SAA.  
A. Interaction with the reverse cholesterol transport. B Induction of 
matrix metalloproteinases that are able to degrade the extracellular 
matrix. C. Promoting binding of HDL to proteoglycans in the vessel 
wall. D. Stimulation of proteoglycan synthesis in the vessel wall. E. 
Induction of foam cell formation. F. Stimulation of cytokine and 
chemokine synthesis. G. Induction of endothelial adhesion molecules 
production. H. Acting as a chemoattractant for monocytes and 
neutrophils.        Picture by J. Carlsten 
Adipose tissue-derived serum amyloid A and adipose tissue macrophages in metabolic disease 
12 
The overall aim of this thesis was to investigate factors within the adipose 
tissue that could contribute to the development of obesity-related disorders 
such as insulin resistance and atherosclerosis.  
The specific aims of the different studies were:  
I. To elucidate whether there are obesity-independent links between 
macrophage gene expression in adipose tissue and metabolic 
dysfunction in humans. 
 
II. To establish a transgenic mouse model with adipose tissue-specific 
expression of human SAA1 as a tool for studies of the role of adipose 
tissue-derived SAA in metabolic disease. 
 
III. To test the hypothesis that adipose tissue-derived human SAA can 
act as a local and systemic regulator of insulin sensitivity and 
inflammation.  
 
IV. To investigate whether adipose tissue-derived human SAA plays a 
role in the development of atherosclerosis in mice. 
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The regional Ethics Committee in Gothenburg, Sweden approved the human 
studies. All subjects received written and oral information about the study 
before giving written consent to participate.  
All study protocols involving animals were approved by the local ethics 
committee for animal studies at the administrative court of appeals, 
Gothenburg, Sweden.  
 
The SOS Sib Pair study consists of 732 individuals in 154 nuclear families 
containing sibling pairs with a BMI difference of more than 10 units. Data 
from a group of parents (n = 88) and an offspring group (n = 357) were used 
in paper I. Only the most extreme siblings according to BMI in each family 
were used for comparisons between lean and obese which resulted in 78 pairs 
of sisters and 12 pairs of brothers. The supplementary data in paper I display 
the different study group characteristics in the SOS Sib Pair study.  
The participants in the SOS Sib Pair study are very well characterized. 
Fasting blood samples were obtained and blood chemistry analyses were 
performed at the Department of Clinical Chemistry, Sahlgrenska University 
hospital. Frequent-sampling intravenous glucose tolerance test was 
performed and data were subjected to minimal model analysis to assess 
estimates of insulin sensitivity. Measurement of body composition was made 
with dual-energy x-ray absorptiometry (DEXA) at Sahlgrenska University 
Hospital. Subcutaneous adipose tissue biopsies were obtained by needle 
aspiration in the paraumbilical area during local anesthesia and were snap 
frozen in liquid nitrogen, stored at -80°C and subsequently used for mRNA 
extraction and DNA microarray analysis. 
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Six patients with recently diagnosed type 2 diabetes mellitus and seven BMI- 
and sex-matched non-diabetic controls were enrolled in this study. Blood 
samples were obtained from fasting participants, blood chemistry analyses 
were performed and adipose tissue biopsies were obtained as described 
above. RNA was extracted and DNA Microarray analysis was performed.    
 
 
A transgenic mouse model with specific expression of the human SAA1 gene 
in adipose tissue was established. In brief, a gene construction with the 
human SAA1 gene under the control of the adipocyte-specific fatty acid 
binding protein 4 promoter (aP2) was created (Figure 2). A SV40 
polyadenylation sequence was ligated to the construction downstream the 
aP2-hSAA1 sequence. A rabbit beta-globin intron was inserted as an internal 
control upstream of the polyadenylation SV40 sequence but downstream the 
aP2-hSAA1 sequence.The gene construction was injected into fertilized eggs 
from C57BL/6 females using pronuclei injection and the eggs were then 
implanted in pseudopregnant females. DNA was extracted from tail biopsies 
and transgenic mice were identified using polymerase chain reaction (PCR). 
Subsequent breeding was performed with C57BL/6 mice to generate 
heterozygous hSAA+/- mice and wild type littermates.  
Figure 2. Schematic representation of the aP2 promoter/hSAA1gene 
construction. Dotted box represent the aP2 promoter, hatched box rabbit β-
globin intron, grey box polyadenylation signal.  
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In the experimental set-up in paper II and paper III, groups of mice were 
given pelleted high fat diet (60 kcal% fat) from 13 or 10 weeks of age, 
respectively, until the end of the experiment. In paper IV, the hSAA1+/- mice 
were crossbred with apoE-/- mice to obtain hSAA1+/-/apoE-/- mice to study the 
effect of adipose tissue-derived human SAA on the development of 
atherosclerosis in mice. The hSAA+/-/apoE-/- mice and their wt/apoE-/- 
littermates were fed normal chow diet during the experiment.  
 
The polymerase chain reaction (PCR) is the basic step in genotyping 
methods. The PCR method was developed in the 1980s and allow rapid 
amplification of DNA sequences [176]. The PCR is based on thermal 
cycling. In the first step, the reaction solution heats up and allow the DNA 
template strands to open up and enables synthesis of the DNA region of 
interest.  Primers, complementary DNA sequences, decide which region of 
the DNA template that will be amplified. The primers hybridize to the 
complementary DNA when the working solution is cooled down. Then, after 
heating up the working solution again, the DNA polymerase will create a 
complementary DNA strand from nucleotides. The newly synthesized DNA 
strands will function as DNA template which creates a chain reaction where 
the number of DNA transcript will increase exponentially.  
In this thesis genotyping of mice was performed in paper, II, III and IV.  The 
amplification products and a DNA-ladder were run on an agarose gel with 
ethidium bromide or SYBR-safe DNA gel stain. The DNA-ladder and the 
amplification product were detected by UV-light.   
 
RNA extraction is the first step in gene expression analysis. Many different 
protocols are provided for RNA extraction but most of them are based on the 
original Chomczynski protocol from 1987 [177-179]. The RNA is separated 
from DNA and proteins in the cell lysate by adding guanidium thiocanate, 
sodium acetate, phenol and chloroform and subsequent centrifugation. The 
RNA will then stay in the upper aqueous phase which can be collected, 
undergo further washing step and precipitation [178]. Today, the RNA 
extraction can be performed with commercially available kits. 
The RNA extraction has to be performed in ribonuclease free environment 
otherwise the RNA will be degraded. For gene expression analysis 
complementary DNA (cDNA) is synthesized from the extracted RNA using 
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reverse transcriptase. RNA extraction for subsequent gene expression 
analysis was performed in all papers in this thesis.  
 
The gene expression of many different genes can be measured 
simultaneously by DNA microarray analysis. DNA microarrays are based on 
the principle that DNA molecules hybridize to complementary DNA strands 
[180-182]. A DNA microarray chip is constructed so that oligonucleotides 
corresponding to a gene sequence are placed on a known position on a solid 
surface. The cDNA synthesized from the RNA extraction is transcribed into 
biotinylated cRNA which can hybridize to the oligonucleotides on the 
surface. In the detection step of the analysis, biotin binds streptavidin that are 
linked to fluorescent phycoerythrin and a fluorescent signal is emitted. The 
intensity of the fluorescence signal reflects the expression level the gene of 
interest.  
DNA microarray analysis was performed in paper I in two study populations 
to investigate the gene expression of macrophage markers in subcutaneous 
adipose tissue in relation to metabolic and anthropometric measurements. In 
the SOS Sib Pair study, the Human Genome U133 Plus 2.0 Gene Chip was 
used which contains over 54 000 oligonucleotide probe sets which covers 
most of the human genes. The Gene 1.0 ST arrays from Affymetrix, 
containing over 28 000 oligonucleotide probe sets  was used in the patients 
with type 2 diabetes mellitus and their BMI-matched healthy controls. The 
DNA microarray analysis data was analyzed using the robust multi-chip 
average (RMA), which  is the most common algorithm for processing DNA 
Microarray gene expression data today [183].  
As with regular PCR, real-time PCR technique uses primers flanking the 
DNA sequence of interest and a DNA polymerase synthesizing the DNA 
sequence from nucleotides in the reaction mixture. However, the reaction 
mixture also contains a probe that binds to the middle of the DNA sequence. 
The probe contains a fluorescence reporter molecule and a quencher which 
inhibits the emission of fluorescence from the reporter. When the DNA-
polymerase synthesizes the new DNA-strand, the quencher is separated from 
the reporter. This terminates the inhibition and emission of fluorescence can 
occur. Depending on the amount of target template cDNA in the sample, 
there is a massive increase of fluorescence in the sample at a certain time 
point [184]. Quantification of the gene expression can be performed using a 
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standard curve or with relative quantification with a housekeeping gene 
whose expression is relatively stable [184-186].      
Gene expression analysis with TaqMan real-time PCR was performed in 
paper II, III and IV. The gene expression of human SAA1/2 and mouse Saa3 
in adipose tissue were explored in paper II, III and IV. Additional analysis of 
the expression of macrophage markers and genes related to insulin sensitivity 
in the adipose tissue were performed in paper III.  
 
The Fast Protein Liquid Chromatography (FPLC) technique is used to purify 
a mixture of proteins. The methodology is based on the phenomenon that 
proteins display different affinity for different materials. The two materials in 
a FPLC consist of a mobile phase (elution buffer) and a porous solid 
(stationary) phase. The protein mixture is applied to the solid phase and the 
proteins bind to this. A constant flow of elution buffer but with successively 
increasing concentration is then applied. During this process the proteins 
dissociate from the solid phase and are then found in the effluent fractions. 
The proteins are detected by absorption of UV-light. Each protein appears in 
the effluent as a peak in protein concentration and the eluate can be collected 
for further analysis. FPLC has been performed in paper II in order to measure 
the concentration of human SAA and cholesterol in different FPLC-fractions.    
ELISA is used to measure antigen or proteins in a liquid sample. There are 
different examples of ELISAs but most set ups involve two antibodies. The 
primary antibody detects the antigen/protein of interest and the secondary 
antibody either binds the primary antibody or the protein of interest. The 
secondary antibody carries an enzyme. When the substrate of the enzyme is 
added to the working solution it will lead to a shift in color which is related to 
the amount of target protein in the sample. The color of the sample is 
measured by a spectrophotometer [187-189] and analyzed in relation to a 
standard curve with known concentration of the protein of interest.     
Measurement of human SAA and mouse SAA in plasma was performed in 
paper II, III and IV. Blood levels of insulin were measured in paper II and 
paper III. In paper III, a multiplex assay was used to measure 
proinflammatory markers in plasma from male mice fed a high fat diet.   
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Dual energy x-ray absorptiometry is a method used to estimate total and 
regional percentages of body fat. The technology is based on two X-rays with 
different energies. It measures the photon attenuation, considered to reflect 
the tissue composition, in each pixel of a picture. The DEXA analysis can 
differentiate between fat mass, lean tissue mass and bone mineral mass. The 
method is non-invasive and relatively easy to perform and the radiation dose 
is small in comparison to computed tomography-scans [190].  
Dual energy x-ray absorptiometry was performed in paper I, II and III to 
assess body composition in the SOS Sib Pair study participants and in 
hSAA1 mice and wild type controls.  
 
The minimal model was developed by Dr. Richard Bergman [191] and uses 
the mathematical relationship between glucose and insulin concentrations 
during an intravenous glucose tolerance test to assess insulin sensitivity. The 
parameters estimated in the minimal model have been shown to be highly 
concordant with the glycemic clamp that is considered to be the golden 
standard for insulin sensitivity estimates [192,193].  
In the SOS Sib Pair study, an insulin modified frequent sampling intravenous 
glucose tolerance test was performed [194]. The study participants had to fast 
over night before the test. A bolous dose of glucose (300 mg/kg) was given 
intravenously over 2 minutes. An intravenous dose of insulin was 
administrated 20 minutes after the glucose administration (0.03U/kg for 
subjects with BMI below 35 kg and 0.05 U/kg for subjects with BMI over 
35). Blood samples were frequently collected for measurements of plasma 
glucose and serum insulin determinations at scheduled time points. Data were 
then analyzed using the MINMOD computer program (Millennium 6.02 
version, Los Angeles, CA) to assess estimates of insulin sensitivity, Si [195].  
An oral glucose tolerance test is commonly used in the clinic to measure 
glucose tolerance and to estimate insulin resistance. A single oral dose of 
glucose is administrated and blood glucose and blood insulin are measured at 
Sofie Ahlin 
19 
pre-determined time points during two hours to see how the body responds to 
glucose and how quickly glucose is cleared from the circulation.  
Oral glucose tolerance tests were performed in hSAA1 mice and wild type 
controls at 21 weeks of age in paper III. In our mice, a single dose of glucose 
(400 mg/ml, 2 g/kg) was administrated by oral gavage after a 4 h fast. 
Circulating levels of insulin and glucose was measured after 0, 5, 10, 15, 30, 
60, 120 minutes.  
 
Quantification of atherosclerotic lesions can be performed using lipid staining 
of the luminal surface of aortas prepared en face or with histological analysis 
of cross sectional parts of the aortic root. Different parts of the aortas display 
different susceptibility to develop atherosclerotic lesions. For quantification 
analysis the results are often reported separately for the different parts.  
Lipid staining with Sudan IV has been performed in en face prepared aortas 
from hSAA1+/-/ApoE-/- mice in paper IV to quantify extent of aortic lesions. 
Computer-assisted image analysis for quantification of atherosclerotic lesion 
area was performed with BioPix IQ 2.2.1 (Gothenburg, Sweden). The 
atherosclerotic lesion areas (expressed as the percentage of total area) were 
analyzed in total aorta, the aortic arch, the thoracic aorta and the abdominal 
aorta.  
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Macrophage gene expression in adipose tissue is associated with insulin 
sensitivity and serum lipid levels independent of obesity.   
Obesity leads to an increased macrophage infiltration in the adipose tissue in 
both mice and humans. In paper I, we have investigated whether markers for 
macrophages in the adipose tissue are associated with metabolic disturbances 
independent of obesity in humans. In addition, we have evaluated different 
macrophage markers that can be used for future studies of macrophages in 
adipose tissue.     
Putative macrophage markers were selected from the literature. The 
evaluation of thirty-one putative macrophage markers was performed in two 
steps. First, putative macrophage markers were examined in a human 
immune cell transcriptome data set to ensure that no other immune cell 
displayed high expression of these genes. Nineteen genes displayed at least a 
two-fold higher expression in macrophage-like cell types compared to other 
immune cells and were selected for further evaluation. In the next step, the 
adipose tissue gene expression of putative macrophage markers was 
evaluated by pair-wise correlation analysis in the offspring group of the SOS 
Sib Pair study. In this step, one marker was removed due to low level of 
association with the other macrophage markers.  
The adipose tissue gene expression of macrophage markers was analyzed in 
relation to obesity by comparing the adipose tissue expression in lean versus 
obese siblings in the SOS Sib Pair study. All of the macrophage markers 
displayed an increased expression in the adipose tissue of obese siblings 
compared to their lean counterparts. On average the expression of 
macrophage markers was increased two-fold in obese siblings.   
The gene expression levels of the selected macrophage markers were then 
analyzed in relation to anthropometric and metabolic measurements in the 
offspring group of the SOS Sib Pair study. All anthropometric and metabolic 
measurements were significantly associated with the gene expression of 
macrophage markers. The strongest associations were found to measures of 
adiposity (BMI, fat mass and percentage body fat assessed by DEXA) and to 
serum levels of insulin and C-peptide. Furthermore there was a strong 
negative association between the expression of macrophage markers and 
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HDL-cholesterol and insulin sensitivity. The same analysis was repeated with 
a BMI-adjustment to investigate the influence of obesity (Figure 3). The 
associations were weakened but the expression of macrophage markers was 
still associated to insulin sensitivity, serum levels of insulin, C-peptide, HDL-
cholesterol and triglycerides. 
To further confirm the results, the analysis was repeated in the parent group 
of the SOS Sib Pair study. In line with the results from the offspring group, 
the gene expression of several of the macrophage markers was still 
significantly associated with insulin sensitivity, serum levels of insulin, 
HDL-cholesterol and triglycerides after BMI-adjustment. 
Figure 3. Associations between adipose tissue expression of macrophage 
markers and metabolic and anthropometric measurements in the offspring group 
of the SOS Sib Pair study. The analysis was adjusted for BMI, age, sex and non-
independence among related individuals. Macrophage markers are indicated by 
their gene symbol. The colors represent the level of association (parameter 
estimate) of the various measurements. Green color represents a significant 
positive association and red color represents a significant negative association. 
White color represents a non-significant association. The median parameter 
estimate is shown in the bottom row. BP = blood pressure, SR = sedimentation 
rate, CRP = C-reactive protein   
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The link between gene expression of macrophage markers and insulin 
sensitivity was further investigated by comparing the expression of the 18 
macrophage markers in patients with type 2 diabetes mellitus and BMI-
matched healthy controls. Fifteen of the eighteen macrophage markers 
displayed significantly higher expression in the patients with type 2 diabetes 
mellitus.   
 
Establishment of a transgenic mouse model specifically expressing human 
serum amyloid A in the adipose tissue.  
Serum levels of SAA are linked to insulin resistance and atherosclerosis. 
Results from in vitro studies have suggested a role for SAA in these 
processes. In obesity, the majority of SAA is derived from adipose tissue 
during the non-acute phase. We therefore established a hSAA1 transgenic 
mouse model to investigate the role of adipose tissue-derived SAA in 
metabolic disease in vivo.  
Using pronuclei injection, three hSAA1+/- transgenic founder mice on a 
C57BL/6 background were generated and one strain was later established. In 
this paper, only male mice of F2 generation or later were used. The mice 
were fed normal chow until 12 weeks of age when they were divided into 
four groups where two groups (hSAA1 mice, n = 7 and wild type mice, n = 8) 
were fed a high fat diet for 18 weeks and two groups (hSAA1 mice, n = 10 
and wild type mice, n = 10) continued to be fed normal chow. The study was 
ended when the animals were 30 weeks of age.  
Analysis of human SAA1 mRNA levels in hSAA1 mice revealed a specific 
expression of hSAA1 in the different adipose tissue depots but barely 
detectable mRNA levels in the other tissues investigated (muscle, kidney, 
heart and liver) (Figure 4). The mRNA levels of hSAA1 in the adipose tissue 
depots were similar in hSAA1 mice fed normal chow and mice fed a high fat 
diet. As expected, wild type littermates did not display any detectable hSAA1 
mRNA levels in any of the investigated tissues.  
The hSAA1 mice fed a high fat diet displayed increased levels of human 
SAA compared to the hSAA1 mice fed with normal chow (Table 1, p < 
0.001). As expected, the human SAA protein was undetectable in the 
circulation of wild type animals. The hSAA1 mice fed with a high fat diet 
displayed a significant reduction in mRNA levels of the endogenous mouse 
Saa3 in the epididymal adipose tissue compared to their wild type controls on 
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the same diet (p < 0.05). However, a similar mRNA level of Saa3 was seen in 
hSAA1 and wt mice fed with normal chow.  The circulating levels of mouse 
SAA were increased in the groups fed with a high fat diet (p < 0.001). 
However, no differences between hSAA1 and wild type mice in the same diet 
groups were found.   
The hSAA1 mice displayed no visible phenotype but had a slightly lower 
body weight at 11 weeks of age (25.0 ± 2.1 g, n = 18) compared to their wild 
type littermates (26.3 ± 2.0 g, n= 19, p =0.046). Despite an initial weight 
difference, similar growth was observed in hSAA1 mice and wild type mice 
fed the same diet. In line with these results, similar amount of total body fat 
was seen in hSAA1 mice and wild type mice fed the same diet at 29 weeks of 
age.  
At 28 weeks of age, the groups of animals fed a high fat diet were fasted for 4 
hours and blood glucose and blood insulin were measured. Total cholesterol 
and triglycerides were measured in plasma samples at the end of the 
experiment. Similar levels of glucose, insulin, total cholesterol and 
triglycerides were seen in hSAA1 and wild type mice in the same diet groups 
(Table 1). 
Figure 4. hSAA1 gene expression in epididymal white adipose tissue (eWAT), 
retroperitoneal white adipose tissue (rWAT), brown adipose tissue (BAT), 
muscle, kidney, heart and liver from hSAA1 mice fed normal chow (n = 7). 
hSAA1 gene expression in eWAT and rWAT from hSAA1 mice fed a high fat 
diet (n = 10).  
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Plasma levels of human SAA were analyzed in relation to body fat assessed 
by DEXA, body weight, plasma levels of cholesterol and triglycerides, blood 
glucose and blood insulin. Plasma levels of human SAA were significantly 
associated with amount of body fat, body weight and levels of total 
cholesterol. Body weight and amount of body fat were also significantly 
associated with plasma levels of mouse SAA. 
Lipoprotein cholesterol and triglyceride content were similar in hSAA1 mice 
and wild type controls when analyzed by FPLC gel filtration (Figure 5). The 
hSAA levels peaked in the HDL containing fractions from hSAA1 mice. 
There was a significant increase of hSAA levels in the HDL-containing 
fractions from hSAA1 mice fed high fat diet compared to those fed with 
normal chow. Furthermore, hSAA was also present in HDL fractions isolated 
by ultracentrifugation from hSAA1 mice fed with normal chow. 
 
 
 
 
 
 wt NC 
 
hSAA1 NC 
 
wt HFD hSAA1 HFD 
 
hSAA, ug/mL - 4.8 ± 0.5*** - 37.7 ± 4.0*** 
mSAA, 
ug/mL 
5.5 ± 1.7*** 3.7 ± 0.8*** 25.8 ± 
2.9*** 
25.6 ± 3.8*** 
Cholesterol, 
mmol/L 
3.0 ± 0.2 3.0 ± 0.4 5.5 ± 0.9 5.3 ± 1.0 
Triglycerides, 
mmol/L 
0.7 ± 0.08 0.7 ± 0.09 0.52 ± 0.13 0.55 ± 0.09 
Table 1. Plasma levels of human SAA, mouse SAA, total cholesterol and 
triglycerides in hSAA1 mice and wild type mice (wt)  fed with normal chow (NC) 
or high fat diet (HFD). *** p ≥ 0.001.   
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Figure 5. Distribution of cholesterol and human SAA in FPLC fractions.  
A. Cholesterol levels in plasma FPLC fractions from wild type mice (wt) and 
hSAA1 mice fed normal chow (NC) or a high fat diet (HFD). B. Levels of 
human SAA in plasma FPLC fractions from hSAA1 mice fed with normal chow 
(NC) or a high fat diet (HFD) 
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No evidence for a role of adipose tissue-derived serum amyloid A in the 
development of insulin resistance and obesity-related inflammation in 
hSAA1
+/- 
transgenic mice. 
Recombinant human SAA1/2 is a chemoattractant for monocytes and 
neutrophils and serum levels of SAA are linked to insulin resistance. 
However, whether adipose tissue-derived SAA is a chemoattractant in 
adipose tissue, and/or a regulator of insulin resistance is not known.  
In this paper, both female and male hSAA1 mice (females, n = 20, males, n = 
17) and their wild type littermates (females, n = 20, males = 20) were used. 
The mice were fed a normal chow until 10 weeks of age and were then 
divided into groups fed normal chow or a high fat diet for another 12 weeks.  
In line with our previous studies, adipose tissue mRNA levels of hSAA1 
were present in both female and male hSAA1mice and the circulating levels 
of hSAA were increased in animals fed a high fat diet. Mouse Saa3 mRNA 
levels in adipose tissue and plasma levels of mSAA were higher in animals 
fed a high fat diet. There was a significant decrease in gonadal adipose tissue 
mRNA levels of mSaa3 in female hSAA1 mice fed a high fat diet compared 
to their wild type littermates. The same trend was seen in male hSAA1 mice 
fed a high fat diet.  
Figure 6. A. Blood glucose area under the curve (AUC) in male wild type 
mice (white bar) and hSAA1 mice (black bar) fed a high fat diet. B. Blood 
insulin area under curve (AUC) in wild type mice (white bar) and hSAA1 
mice (black bar) fed with high fat diet.  
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Throughout the experiment, similar growth patterns were observed for both 
female and male hSAA1 and wild type mice fed the same diet. In line with 
these results, DEXA-analysis revealed a similar body composition at 18 
weeks of age for hSAA1 and wild type mice in the same diet groups.  
To estimate systemic insulin resistance, oral glucose tolerance tests were 
performed at 21 weeks of age in mice fed a high fat diet. Blood glucose and 
blood insulin area under the curve were similar in hSAA1 and wild type mice 
in both sexes (Figure 6). With the exception of significantly lower blood 
insulin levels 15 minutes after glucose administration in female hSAA1 mice, 
no difference was seen for blood glucose or blood insulin levels at 0, 15, 30, 
60 and 120 minutes after glucose administration. 
To study possible local effects of hSAA on insulin resistance in adipose 
tissue, mRNA levels of genes related to insulin sensitivity were analyzed 
(Figure 7). In male mice, adipose tissue mRNA levels of Irs1, Irs2, Glut4 and 
adiponectin were similar in hSAA1 and wild type controls in the same diet 
groups. This was true for both adipose tissue depots investigated. Male mice 
fed a high fat diet displayed a significant down regulation in the expression of 
all genes related to insulin sensitivity compared to mice fed normal chow. In 
female mice, gonadal and retroperitoneal mRNA levels of genes related to 
insulin sensitivity were similar regardless of genotype except for Glut4 in the 
gonadal depot which was decreased in wild type mice fed a high fat diet.  
mRNA levels of the macrophage markers Cd68 and Emr1 were analyzed in 
retroperitoneal and gonadal adipose tissue depots (Figure 7). Both female and 
male mice displayed increased mRNA levels of macrophage markers when 
fed with high fat diet. However, no differences between hSAA1 and their 
wild type littermates fed with the same diet were found.  
Levels of proinflammatory markers (CXCL1, IFN-γ, IL-10, IL12p70, IL-1β 
and TNF-α) were analyzed in male mice fed a high fat diet. With the 
exception of lower levels of CXCL1 in hSAA1 mice, similar levels of 
proinflammatory markers were seen in hSAA1 mice and wild type mice. 
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Figure 7. Gonadal adipose tissue mRNA level of A. insulin sensitivity-related 
genes and B. macrophage markers in hSAA1 mice and wild type mice (wt) fed 
normal chow (NC) or a high fat diet (HFD). The genes are represented by their 
gene symbol.  
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Adipose tissue-derived human serum amyloid A does not affect 
atherosclerotic lesion area in hSAA
+/-
/ApoE
-/- 
mice.   
Both pro- and anti-atherogenic functions of SAA has been suggested and 
results from in vivo studies display divergent results regarding the role for 
SAA in atherogenesis. Hence, the role of SAA in atherogenesis is still not 
clear.    
Male hSAA1+/- mice (n = 33) and hSAA-/- mice (n = 23) on an ApoE-
deficient background were used in paper IV. The mice were fed normal chow 
for 35 weeks until the end of the experiment.  
Human SAA1 was expressed in gonadal adipose tissue in hSAA1 mice but 
not detectable in wild type mice. Plasma levels of human SAA were in the 
same range as previously reported for hSAA1 mice fed with normal chow. 
mRNA levels of mouse Saa3 in gonadal adipose tissue displayed a trend 
towards down regulation in hSAA1 mice compared to wild type mice. The 
same trend was also seen for plasma levels of mouse SAA.  
The hSAA1 mice and their wild type controls displayed similar plasma levels 
of cholesterol (13.2 ± 0.6 mmol/l and 14.0 ± 0.7 mmol/l, respectively) and 
triglycerides (1.5 ± 0.1 mmol/l and 1.6 ± 0.1 mmol/l, respectively).   
Quantification of atherosclerotic lesion area was performed in en face 
prepared aortas where the atherosclerotic lesions were stained with Sudan IV. 
Computer-assisted image analyses revealed almost identical atherosclerotic 
lesion area in the total aorta in hSAA1 mice and wild type mice (3.09 ± 0.39 
% and 3.08 ± 0.60 %, respectively, p = 0.306). Different trends in 
atherosclerotic lesion area were observed in the sectional analysis of the aorta 
but these were not statistically significant. The hSAA1 mice displayed a trend 
towards increased atherosclerotic lesion area in the aortic arch compared to 
wild type mice (10.62 ± 1.31 % and 8.11 ± 1.22 %, respectively, p = 0.254). 
The opposite trend was observed in the abdominal aorta where the hSAA1 
mice displayed a decrease in atherosclerotic lesion area compared to wild 
type mice (1.43 ± 0.34 % and 3.52 ± 1.21 % respectively, p = 0.720). Similar 
atherosclerotic lesion area was observed in the thoracic aorta for hSAA1 mice 
and wild type mice (0.83 ± 0.15 % and 0.79 ± 0.18, respectively, p = 0.835).  
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Figure 8. Quantification of atherosclerotic lesion area in en face prepared aortas 
from male hSAA1 mice (n = 33) and wild type mice (n = 23) on ApoE-deficient 
background. A. Lesion area with positive Sudan IV staining expressed as the 
percentage of total area of the whole aorta. Data are presented as mean ± SEM. ns = 
non significant with Mann-Whitney U-test. B. Photographs illustrating 
atherosclerotic lesions in wild type and hSAA1 mice.  
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Previous studies have demonstrated an increased infiltration of macrophages 
in obese adipose tissue in both mouse and human [90,91,93,94]. The link 
between obesity and adipose tissue macrophages has been further supported 
as the number of macrophages in adipose tissue decrease with surgery-
induced weight loss [93]. Both weight loss and treatment with 
thiazolidinediones reduce insulin resistance and macrophage infiltration in 
adipose tissue [93,196] which indicates that adipose tissue macrophages are 
involved in the development of insulin resistance. 
We here report associations between expression of macrophage markers in 
adipose tissue and insulin sensitivity and serum lipid levels in a well 
characterized, large study population. Most importantly, this association 
remained, although weaker, when the analysis was adjusted for BMI. 
Furthermore, our data revealed increased gene expression of macrophage 
markers in adipose tissue from patients with type 2 diabetes mellitus 
compared to their BMI-matched non-diabetic controls. This indicates that 
adipose tissue macrophages could be actively involved in the development of 
metabolic disease, such as insulin sensitivity and serum levels of HDL-
cholesterol and triglycerides.  
Macrophages are present in many different tissues in the body and are a 
heterogeneous cell type. The macrophages have important functions in the 
innate immune system and can produce pro-inflammatory cytokines, mediate 
phagocytosis of dead or infected cells and are active in tissue remodeling. In 
2003, two reports established that adipose tissue macrophages are important 
producers of proinflammatory cytokines [90,91]. In vitro studies of 
macrophage function have demonstrated that co-culture of murine 
macrophages and adipocytes blocks the action of insulin in adipocytes [197] 
and that TNF-alpha treatment reduces the expression of insulin sensitivity 
genes in adipocytes  [198,199]. In addition, proinflammatory cytokines down 
regulate the expression of ABCA1 and ABCG1 that are active in the 
cholesterol transport from the cells to HDL [200]. These mechanisms could 
be part of the explanation why increased macrophage infiltration in adipose 
tissue leads to insulin resistance and dyslipidemia. 
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The exact role for macrophages in adipose tissue is hard to study in vivo. Due 
to technical limitations, it is not possible to knockout one cell type in a 
specific tissue. Some conclusions may be drawn from whole-body knockout 
models where genes in inflammatory cascades are deleted. Myeloid specific 
IKK-β knockout mice, where the myeloid cells (e. g. macrophages, dendritic 
cells) do not have the ability to respond to inflammatory stimuli, are more 
insulin sensitive [201,202]. However, it is possible that other myeloid 
immune cells in other tissues contribute to the improved insulin sensitivity. 
Consequently, indirect studies of macrophage infiltration and subsequent 
alterations in metabolic dysfunctions after different interventions such as 
knockout mouse models or transgenic mouse models may be as far as we can 
go to investigate the function of adipose tissue macrophages in vivo. 
Decreased infiltration of macrophages into adipose tissue and, subsequently, 
improved insulin sensitivity was demonstrated in a knockout-model for the 
macrophage chemoattractant MCP-1 receptor, Ccr2 [203]. Conversely, over-
expression of MCP-1 in the adipose tissue of mice increased macrophage 
infiltration into adipose tissue and rendered mice more insulin resistant 
[101,102].  
Different subgroups of macrophages have been identified in the adipose 
tissue. In the adipose tissue of lean individuals, the macrophages are found 
interspersed in the adipose tissue while the macrophages in obese individuals 
form crown-like structures around adipocytes [93,95]. In contrast to 
interspersed macrophages, macrophages in crown-like structures contain lipid 
droplets and resemble the foam cells that are present in atherosclerotic lesions 
[204]. Thus, immunohistological examinations suggest different functions of 
macrophages in lean and obese individuals. 
Macrophages are often classified as proinflammatory macrophages “M1” or 
anti-inflammatory macrophages “M2” depending on which surface markers 
they express in vitro. Data from mice suggest that obesity induces a 
phenotypic switch from anti-inflammatory M2 to pro-inflammatory M1 
macrophages [204]. In vivo polarization of adipose tissue macrophages 
towards a M1 phenotype has been achieved by macrophage-specific deletion 
of the PPAR-γ gene in mice. The M1 polarization made mice more insulin 
resistant, suggesting that M1 macrophages are involved in obesity-related 
insulin resistance [205]. However, other studies have shown that the 
expression of M2 markers that correlates with BMI, indicating that it is 
actually the M2 macrophages that are increased in obesity [206]. 
Furthermore, one study has shown that macrophages are able to express both 
M1 and M2 markers [207]. These data indicate that adipose tissue 
macrophages are not homogenous in phenotype and may exhibit both 
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proinflammatory and anti-inflammatory functions. Hence, using the M1/M2 
classification may be an oversimplification that is more relevant in vitro than 
in vivo. For this reason, we have used many different macrophages markers 
when investigating the expression in adipose tissue and we have decided not 
to classify the markers into M1 and M2 categories.  
Our study is a correlative study of adipose tissue macrophage infiltration, 
estimated by the expression of macrophage markers, in relation to 
anthropometric and metabolic parameters. This means that no causality can 
be determined which is a limitation in our study. Another limitation is that 
the expression of macrophage markers was only studied in the adipose tissue 
and may therefore not investigate the whole complexity of obesity-related 
inflammation. Inflammation is an interplay between different cells and 
cytokines. Recent studies have shown that other inflammatory cells are 
present in the adipose tissue and these may have important roles in metabolic 
disease [100,208-213].  
In conclusion, our study represents a systematic examination of the 
association between gene expression of macrophage markers in adipose 
tissue and metabolic dysfunction. The obesity-independent links between 
macrophages in adipose tissue and insulin sensitivity and serum levels of 
lipids suggests that the increase of macrophages in adipose tissue of obese 
individuals is actively linked to, rather than only a marker of, obesity. Our 
data, together with other recent studies, suggest that adipose tissue 
macrophages play a role in the development of metabolic disease in humans. 
 
In paper II, the establishment and initial characterization of a transgenic 
mouse model with expression of human SAA1 in the adipose tissue were 
reported.  
The mouse is one of the most common experimental animal models used in 
medical research today. There are many different mouse strains for medical 
research of which some develop complex diseases such as obesity, type 2 
diabetes mellitus and cancer [214]. Many strains are a result of constant 
inbreeding so that the individuals in one strain have as identical genetic 
background as possible. The even genetic background makes the inbred 
mouse strains suitable for genetic modifications to study the function of a 
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specific gene [215-218]. We established our hSAA1+/- transgenic mouse 
model on a C57Bl/6 background. The whole genome of the C57Bl/6 strain 
has been surveyed which makes it suitable for genetic modifications. The 
strain is the most commonly used mouse strain for studies on obesity, 
cardiovascular disease and transgenic research.  
Our hSAA1+/- transgenic mice display specific expression of human SAA1 in 
the adipose tissue under the aP2 promoter. mRNA levels of the human SAA1 
is detected in the different adipose tissue depots and only display low levels 
of hSAA1 expression in other tissues investigated. This is of importance 
since much data indicate that the adipose tissue is a main producer of SAA in 
obese humans during non-acute phase [128-131].  
In the acute-phase, the levels of SAA can rise 1000-fold and then decrease to 
normal levels a few days after the inflammatory stimuli have been removed 
[119]. However, in obesity the increase of SAA is moderate and chronic and 
the moderately elevated levels of SAA in obesity are linked to both insulin 
resistance and cardiovascular disease [84,86,89,132,133]. The hSAA1 mice 
fed with normal chow or high fat diet display levels of human SAA 
comparable to lean and obese humans. Hence, the hSAA1 mouse is a new 
model suited to investigate the effects of the chronically elevated levels of 
hSAA derived from adipose tissue.  
Mice also display elevated levels of SAA in the circulation in the obese state 
[148,163]. However, the origin of SAA is different. The homologues of 
SAA1/SAA2 (Saa1/Saa2) in mice only display a limited gene expression in 
adipose tissue and the expression is not affected by diet-induced obesity 
[163]. Instead, a third acute-phase form, Saa3, is expressed in the adipose 
tissue and the expression is increased by high fat diet [163,219]. However, 
Saa3 gene expression in adipose tissue does not contribute to the circulating 
levels of SAA [219] indicating that the moderately elevated levels of SAA 
found in obese mice have a hepatic origin. Thus, adipose tissue-specific 
expression of hSAA1 is important when further investigating local effects of 
SAA in adipose tissue.  
The hSAA was found in the HDL-containing FPLC-fraction in hSAA1 mice. 
This indicates that the human SAA has a functional binding site for HDL and 
that it associates with HDL in the circulation. The binding of SAA to HDL 
may also be of importance for SAA function. Many in vitro studies have used 
a lipid-free form of SAA. The use of lipid-free SAA in experimental set-up 
has been questioned [220] since it does not exhibit the same functions as 
SAA associated to HDL [159,166,221,222]. Hence, results from previous 
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studies using lipid-free SAA can lead to misinterpretation of SAA function in 
the circulation where the majority of SAA is associated with HDL. However, 
it is possible that HDL-free SAA exhibits functions in its local production 
site before it reaches the circulation and associates with HDL. This further 
highlights the importance of a tissue specific production of SAA.  
In our hSAA1 transgenic mouse model we have used transgenic expression 
of the human SAA1 gene in adipose tissue. Many in vitro studies of SAA 
function have used a recombinant form of human SAA, which is a 
combination of the SAA1 and SAA2 isoforms. We and others have shown 
that the recombinant protein does not share the same function as the 
endogenous SAA [174,175,223]. The recombinant protein exhibit 
proinflammatory functions as it activates neutrophils in vitro. In contrast, 
purified endogenous SAA did not have this effect [174,175]. Hence, the 
proinflammatory function that has been ascribed SAA may not be 
physiologically relevant, highlighting the need for in vivo studies to clarify 
the physical roles of SAA.  
In our transgenic mouse model, a human gene is inserted in the mouse 
genome. This does not automatically result in a functional protein or that the 
human protein binds to mouse receptors and exhibit a function. In our 
hSAA1 mice the human SAA protein was detectable by an ELISA indicating 
correct protein folding of the human protein. Furthermore, the endogenous 
Saa3 gene expression in adipose tissue was reduced in hSAA1 mice 
compared to their wild type littermates. This indicates that the human protein 
may exhibit a negative feedback on Saa3 expression in mouse adipose tissue. 
Other studies have shown that adenoviral overexpression of human SAA1 in 
mice results in an increased vascular proteoglycan synthesis [152]. In 
addition, domains of the human SAA protein are functional in mouse J774 
cells (monocyte cell line) by increasing acyl CoA cholesterol acyltransferase 
activity increase in the same range as the mouse SAA [224]. These findings 
further support that human SAA is functional in mice.  
Taken together, the links between circulating levels of SAA and 
cardiovascular disease [84,86,89,132,133,225] and the many in vitro studies 
suggesting a mechanism for SAA in metabolic disease [145,154,162-
164,226] place adipose tissue-derived SAA in focus as a possible player in 
the development of atherosclerosis and insulin resistance. With the 
establishment of our transgenic hSAA1+/- mouse model with specific 
expression of hSAA1 in adipose tissue, we have created an in vivo model 
suited to study the moderately chronic increase of SAA that is associated 
with metabolic disease.   
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In paper III, we have investigated whether adipose tissue-derived hSAA1 
could be linked to obesity, increased macrophage infiltration in adipose tissue 
or insulin resistance. An increase in macrophage infiltration in adipose tissue 
with subsequent decrease in local and systemic insulin sensitivity has 
previously been shown in a mouse model with adipose tissue-specific 
expression of MCP-1 [101,102]. The chemoattractant function of 
recombinant hSAA1/2 and the association between serum levels of SAA and 
insulin resistance [84,89,133,159,160,163,164] indicated that adipose tissue-
derived SAA could have similar effects.  
The hSAA1 mice fed with high fat diet display no increase in blood glucose 
or blood insulin levels during an oral glucose tolerance test. This was 
somewhat unexpected since previous studies have shown an association 
between circulating levels of SAA and insulin resistance in both human and 
mouse studies [84,89,133]. In addition, circulating levels of SAA decrease in 
parallel with an improvement in glycemic status when patients are treated 
with PPAR-γ agonists [133]. However, our results indicate that the 
moderately elevated serum levels of hSAA1 do not affect systemic insulin 
sensitivity in mice.  
Even though the adipose tissue can affect systemic insulin resistance, our 
results from the oral glucose tolerance test do still not rule out the possibility 
that adipose tissue production of human SAA1 may affect local insulin 
sensitivity. In vitro studies of SAA function have shown that recombinant 
human SAA1/2 down regulates genes involved in insulin sensitivity [162-
164]. As expected, genes related to insulin signaling and glucose homeostasis 
(Glut4, Irs1, Irs2, and Adipoq) displayed a significant reduction in both 
gonadal and retroperitoneal adipose tissue depots in male mice fed a high fat 
diet compared with those fed normal chow. The same trend was seen in the 
retroperitoneal depot in female mice. However, no decrease in the expression 
of insulin sensitivity genes was seen in hSAA1 mice compared to wild type 
mice in the same diet groups. Hence, in our mouse model, adipose tissue-
derived hSAA1 does not seem to affect local insulin sensitivity in adipose 
tissue. 
The mRNA levels of the macrophage markers Emr1 and Cd68 in adipose 
tissue was similar in hSAA1 mice and wild type controls. The human 
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recombinant hSAA1/2 is a chemoattractant for neutrophils and monocytes 
[159,160] but the chemoattractant effect of SAA is inhibited by the 
association of SAA to HDL [159]. In the circulation of hSAA1 mice, the 
human SAA is found associated with HDL. Possibly, the human SAA could 
have chemoattractant effects in the adipose tissue before it associates with 
HDL. However, our results do not indicate that this is the case. In the adipose 
tissue, SAA could also possibly interact with macrophage recruitment via up 
regulation of CCL2, a known macrophage chemoattractant [163,226] or 
induction of cell adhesion molecules in endothelial cells [157]. However, we 
found no indication that the adipose tissue-derived hSAA1 increases 
macrophage infiltration in adipose tissue.  
The low-grade inflammation in obesity includes moderately increased levels 
of proinflammatory markers e. g. IL-6, TNF-α and CRP [84,88,227,228]. 
Recombinant human SAA1/2 stimulates cytokine and chemokine expression 
in both macrophage and endothelial cell lines [156,157,169]. It is reasonable 
to believe that the moderately elevated levels of SAA in our mouse model 
could stimulate the production of proinflammatory markers. However, male 
hSAA1 mice fed a high fat diet displayed no increase in the circulating levels 
of proinflammatory cytokines (IFN-γ, IL10, IL12p70, IL-1β, IL-6, TNF-α, 
and CXCL1). The recent findings that recombinant hSAA1/2 induce 
proinflammatory cytokine production in vitro should be interpreted carefully, 
since we previously have shown that the recombinant hSAA1/2 exhibits 
proinflammatory functions that are not shared by the endogenous protein 
[174,175]. Results from our hSAA1 mice provide further support that the 
human SAA1 may not have proinflammatory properties.  
In conclusion, we show that adipose tissue-derived hSAA1 does not affect 
systemic glucose tolerance or local insulin sensitivity; nor does it increase 
obesity-related inflammation in hSAA1 mice.  
 
There are several links between SAA and atherosclerosis. Both mRNA 
encoding SAA and the SAA protein are present in the human and mouse 
atherosclerotic plaque [147-149]. The circulating levels of SAA have been 
suggested to be predictor for cardiovascular disease [86] and the six–month 
mortality in patients with acute myocardial infarction [225]. The role of SAA 
in atherogenesis is much disputed and studies have provided evidence for 
both proatherogenic and anti-atherogenic roles of SAA (See section 1.6.2). 
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However, there are a limited number of in vivo studies investigating the role 
of SAA in atherosclerosis development.  
Mice do not normally develop atherosclerosis and the feeding of cholesterol-
rich diets only leads to the early atherosclerotic lesions, “fatty streaks”, in 
C57BL/6 mice [229]. Thus, to study atherosclerotic development special 
mouse strains that develop atherosclerosis are needed. In paper IV, hSAA1 
mice were crossbred with ApoE-/- mice to generate hSAA1+/-/ApoE-/- mice 
and hSAA1-/-/ApoE-/- mice. The ApoE-/- mouse model is, together with the 
Ldlr-/- mouse, the most common mouse model for atherosclerotic research 
[230-232]. The genetic deficiency of the apolipoprotein E or the LDL-
receptor leads to hypercholesterolemia and development of atherosclerotic 
lesions. The atherosclerotic development can be accelerated in these models 
by feeding the mice a cholesterol-rich diet. However, the ApoE-/- mice are 
hypercholesterolemic and develop atherosclerotic lesions even when fed a 
normal chow diet [229,233]. In paper IV, the mice were fed with normal 
chow for 35 weeks to minimize the risk that the severe hypercholesterolemia 
present in ApoE-/- mice fed a high fat diet would mask possible differences in 
atherosclerotic development.     
Our data from the hSAA1 mice reveal no differences in atherosclerotic lesion 
area in any section of the aorta in hSAA1 mice compared to their wild type 
littermates. This is in line with a previous study showing that over-expression 
of human SAA1 using adenovirus in ApoE mice fed normal chow had no 
effect on atherosclerosis development [152]. Other studies investigating the 
effect of SAA in atherogenesis display divergent results. Lenti-viral 
expression of mouse SAA1 in ApoE-/- mice fed normal chow for 14 weeks 
accelerated the atherosclerotic lesion progress whereas no difference was 
seen in ApoE-/- mice fed high fat diet [234]. In contrast, liposomal 
administration of mouse SAA2 peptides reverses and prevents atherosclerotic 
lesion development in ApoE-/- mice [224].  
The divergent results from in vivo studies of SAA function in atherogenesis 
may depend on different isoforms, source and expression of SAA. The use of 
lentiviral expression of mouse SAA1 resulted in an increase of 
atherosclerotic lesion area in ApoE -/- mice fed with normal chow [234]. The 
levels of mouse SAA in these mice were in the same range as the human 
SAA in our hSAA1 mouse fed a high fat diet. If these levels are comparable 
is not clear. However, the overexpression site of mSAA1 was not indicated or 
investigated which makes it impossible to draw any conclusions on the 
impact of SAA production site of the development of atherosclerosis. 
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Furthermore, our study does not leave out the opportunity that a possible 
local production of SAA in the vessel wall affects atherogenesis.   
Atherosclerosis is an inflammatory condition with a local inflammation in the 
vessel wall. It is possible that the moderately increased levels of SAA in the 
circulation is induced by the local inflammatory process and acts as a marker 
for atherosclerosis. However, results presented here do not support a causal 
role for the adipose tissue-derived SAA in atherosclerosis development. 
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In this thesis, adipose tissue-derived SAA and adipose tissue macrophages 
have been investigated as possible factors behind obesity-related disorders.  
The main findings of this thesis are summarized in figure 9.  
We have shown that macrophage infiltration in human adipose tissue, 
estimated from mRNA levels of macrophage markers, is increased in obesity 
and type 2 diabetes mellitus. The macrophage gene expression in adipose 
tissue is linked to insulin sensitivity and serum lipid levels and this link 
remained significant after adjustment for BMI. Hence, our data suggest that 
adipose tissue macrophages may play a role in the development of insulin 
resistance and dyslipidemia and that macrophage infiltration should be 
considered as a marker of metabolic disease.    
We have established a new hSAA1+/- transgenic mouse model to investigate 
the effects of adipose tissue-derived hSAA1 on metabolic disease. Firstly, the 
hSAA1 mice have a specific expression of human SAA1 in the adipose tissue 
and the human SAA protein is found in the circulation at levels similar to 
those found in lean and obese humans. Secondly, the human SAA is found 
associated with HDL in the circulation which previously has been shown to 
be important for SAA function. Hence, the hSAA1 mice display important 
features for investigating the function of adipose tissue-derived human SAA 
in vivo.   
During an oral glucose tolerance test, hSAA1 mice displayed similar levels of 
blood glucose and blood insulin as their wild type controls. In addition, no 
decrease in mRNA levels of genes related to insulin sensitivity was found in 
adipose tissue. The mRNA levels of macrophage markers were similar in 
hSAA1 mice and wild type controls. Circulating levels of proinflammatory 
markers were not increased in hSAA1 mice. This taken together, we found no 
evidence that adipose tissue-derived human SAA1 acts as a systemic or local 
regulator of insulin sensitivity in mice. Our data do not support a role for 
adipose tissue-derived human SAA1 in macrophage recruitment into adipose 
tissue or that hSAA could be an important inducer of circulating 
proinflammatory markers in mice.   
Analyses of en face prepared aortas displayed similar atherosclerotic lesion 
areas in hSAA1+/- /ApoE-/- mice and hSAA1-/-/ApoE-/- mice. Thus, our data 
suggests that adipose tissue-derived human SAA1 does not have a major 
impact on atherogenesis in mice.  
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Figure 9. Main findings in this thesis. 1. Adipose tissue gene expression of 
macrophage markers is associated with insulin sensitivity and serum lipid levels 
independent of obesity in human. 2. Findings from the initial characterization of 
our hSAA1 transgenic mouse model specifically expressing human SAA1 in the 
adipose tissue. The mouse model mimics the human non-acute phase with: a. 
Specific hSAA1 expression in the adipose tissue. b. Levels of hSAA in the 
circulation which resembles those seen in lean and obese human. c. The human 
SAA is found associated to HDL. 3. The hSAA1 mice do not display alterations in 
systemic glucose tolerance. 4. The adipose tissue-derived hSAA1 does not down 
regulate insulin sensitivity genes in adipose tissue. 5. The adipose tissue-derived 
hSAA1 does not affect mRNA levels of macrophage markers in the adipose 
tissue. 6. Levels of proinflammatory markers are not increased in hSAA1 mice. 7. 
Adipose tissue-derived hSAA does not affect atherosclerotic lesion area in hSAA1 
mice.                     Picture by J. Carlsten. 
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